You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 21, 2024

Investigational Drug Information for Enobosarm


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Enobosarm?

Enobosarm is an investigational drug.

There have been 11 clinical trials for Enobosarm. The most recent clinical trial was a Phase 3 trial, which was initiated on October 12th 2021.

The most common disease conditions in clinical trials are Breast Neoplasms, Urinary Incontinence, Stress, and Urinary Incontinence. The leading clinical trial sponsors are GTx, Veru Inc., and Martin Performance.

There are thirty-seven US patents protecting this investigational drug and six hundred and fifty-nine international patents.

Recent Clinical Trials for Enobosarm
TitleSponsorPhase
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast CancerVeru Inc.Phase 2
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerVeru Inc.Phase 3
Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary IncontinenceGTxPhase 2

See all Enobosarm clinical trials

Clinical Trial Summary for Enobosarm

Top disease conditions for Enobosarm
Top clinical trial sponsors for Enobosarm

See all Enobosarm clinical trials

US Patents for Enobosarm

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Enobosarm ⤷  Sign Up SARMs and method of use thereof University of Tennessee Research Foundation (Knoxville, TN) ⤷  Sign Up
Enobosarm ⤷  Sign Up Selective androgen receptor degrader (SARD) ligands and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) GTX, INC. (Memphis, TN) ⤷  Sign Up
Enobosarm ⤷  Sign Up Selective androgen receptor degrader (SARD) ligands and methods of use thereof GTX, INC. (Memphis, TN) ⤷  Sign Up
Enobosarm ⤷  Sign Up Selective androgen receptor modulator and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) ⤷  Sign Up
Enobosarm ⤷  Sign Up Selective androgen receptor degrader (SARD) ligands and methods of use thereof GTX, INC. (Memphis, TN) UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) ⤷  Sign Up
Enobosarm ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Enobosarm

Drugname Country Document Number Estimated Expiration Related US Patent
Enobosarm Argentina AR061980 2026-07-12 ⤷  Sign Up
Enobosarm Argentina AR062536 2026-07-12 ⤷  Sign Up
Enobosarm Austria AT344233 2020-08-24 ⤷  Sign Up
Enobosarm Austria AT423092 2020-08-24 ⤷  Sign Up
Enobosarm Austria AT430125 2020-08-24 ⤷  Sign Up
Enobosarm Austria AT526959 2020-08-24 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.